By Josh Beckerman
Shares of Checkpoint Therapeutics rose 4.6% to $3.84 in post-market trading after the Food and Drug Administration approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, the first-ever approval for the company.
Checkpoint said in July the FDA accepted for review its resubmission of the Biologics License Application and set a Prescription Drug User Fee Act goal date of Dec. 28.
The agency issued a Complete Response Letter for the application in December 2023. The letter cited findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturer. The letter didn't state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab, the company said at the time.
Checkpoint said it believes Unloxcyt offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than PD-1, to release the inhibitory effects of PD-L1 as part of the anti-tumor immune response.
The approval provides an opportunity to compete in a U.S. market estimated to exceed $1 billion annually, the company said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 13, 2024 19:09 ET (00:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。